Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SCT400, a Recombinant Chimeric Anti-CD20 Monoclonal Antibody，in Patients With CD20+ B-cell Non Hodgkin's Lymphoma.

NCT02206308 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.

NCT NCT02206308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02206308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SCT400, a Recombinant Chimeric Anti-CD20 Monoclonal Antibody，in Patients With CD20+ B-cell Non Hodgkin's Lymphoma.
Lead sponsor
Sinocelltech Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2012
Completion date
July 31, 2013
Enrollment
15 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non hodgkin's lymphoma